We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Aurora Cannabis Inc. (ACB) Dips More Than Broader Markets: What You Should Know
Read MoreHide Full Article
Aurora Cannabis Inc. (ACB - Free Report) closed at $9.60 in the latest trading session, marking a -1.34% move from the prior day. This move lagged the S&P 500's daily loss of 0.35%. Meanwhile, the Dow lost 0.41%, and the Nasdaq, a tech-heavy index, lost 0.07%.
Prior to today's trading, shares of the company had gained 37.62% over the past month. This has outpaced the Medical sector's gain of 4.43% and the S&P 500's gain of 3.21% in that time.
Investors will be hoping for strength from ACB as it approaches its next earnings release. The company is expected to report EPS of -$0.19, up 91.2% from the prior-year quarter. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $55.25 million, up 30.16% from the year-ago period.
For the full year, our Zacks Consensus Estimates are projecting earnings of -$1.16 per share and revenue of $232.82 million, which would represent changes of +59.44% and +12.04%, respectively, from the prior year.
Investors might also notice recent changes to analyst estimates for ACB. These revisions typically reflect the latest short-term business trends, which can change frequently. As a result, we can interpret positive estimate revisions as a good sign for the company's business outlook.
Research indicates that these estimate revisions are directly correlated with near-term share price momentum. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system.
Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. Over the past month, the Zacks Consensus EPS estimate remained stagnant. ACB currently has a Zacks Rank of #3 (Hold).
The Medical - Products industry is part of the Medical sector. This group has a Zacks Industry Rank of 119, putting it in the top 47% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Make sure to utilize Zacks. Com to follow all of these stock-moving metrics, and more, in the coming trading sessions.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Aurora Cannabis Inc. (ACB) Dips More Than Broader Markets: What You Should Know
Aurora Cannabis Inc. (ACB - Free Report) closed at $9.60 in the latest trading session, marking a -1.34% move from the prior day. This move lagged the S&P 500's daily loss of 0.35%. Meanwhile, the Dow lost 0.41%, and the Nasdaq, a tech-heavy index, lost 0.07%.
Prior to today's trading, shares of the company had gained 37.62% over the past month. This has outpaced the Medical sector's gain of 4.43% and the S&P 500's gain of 3.21% in that time.
Investors will be hoping for strength from ACB as it approaches its next earnings release. The company is expected to report EPS of -$0.19, up 91.2% from the prior-year quarter. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $55.25 million, up 30.16% from the year-ago period.
For the full year, our Zacks Consensus Estimates are projecting earnings of -$1.16 per share and revenue of $232.82 million, which would represent changes of +59.44% and +12.04%, respectively, from the prior year.
Investors might also notice recent changes to analyst estimates for ACB. These revisions typically reflect the latest short-term business trends, which can change frequently. As a result, we can interpret positive estimate revisions as a good sign for the company's business outlook.
Research indicates that these estimate revisions are directly correlated with near-term share price momentum. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system.
Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. Over the past month, the Zacks Consensus EPS estimate remained stagnant. ACB currently has a Zacks Rank of #3 (Hold).
The Medical - Products industry is part of the Medical sector. This group has a Zacks Industry Rank of 119, putting it in the top 47% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Make sure to utilize Zacks. Com to follow all of these stock-moving metrics, and more, in the coming trading sessions.